<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970489</url>
  </required_header>
  <id_info>
    <org_study_id>IND-104364</org_study_id>
    <nct_id>NCT00970489</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation</brief_title>
  <acronym>OPERA</acronym>
  <official_title>(OPERA)Randomized Clinical Trial to Examine Whether Peri-operative Intake of n-3 Polyunsaturated Fatty Acids Will Reduce the Occurrence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The OPERA Investigators</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a large multi-center study to examine whether peri-operative intake of n-3
      polyunsaturated fatty acids (PUFA) will reduce the occurrence of post-operative atrial
      fibrillation or flutter (AF) in patients undergoing cardiac surgery (CS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any First Post-op Atrial Fibrillation or Flutter (AF)</measure>
    <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
    <description>Primary: Occurrence of post-CS AF (atrial fibrillation or flutter) of at least 30 seconds duration and confirmed by rhythm strip or 12-lead ECG. This will include definite AF and probable AF (SVT likely to be AF depending on rate and other characteristics).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-op Af</measure>
    <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
    <description>Secondary AF endpoints included post-op AF that was sustained (&gt;1 hour), symptomatic, or treated with pharmacological or electrical cardioversion; post-op AF excluding atrial flutter; time to first post-op AF; and the number of post-op AF episodes per patient. OPERA also evaluated the total number of in-hospital days in which any post-op AF, including sustained post-op AF, was present; and the proportion of in-hospital days free of any post-op AF. All potential episodes of post-op AF and other tachyarrhythmias were reviewed and adjudicated by a centralized Events Committee of cardiac electrophysiologists. Additional endpoints included resource utilization, major adverse cardiovascular events (MACE), arterial thromboembolism, and 30-day mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Arrhythmias</measure>
    <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
    <description>The first 3 suspected episodes of atrial fibrillation or flutter of at least 30 sec duration following randomization were documented, including the following information:
Printed or digital rhythm strip and/or 12-lead ECG.
Recording of time of onset and time of cessation.
Additional documentation of temporally associated signs of symptoms, such as new or worsening chest pain, shortness of breath, or lightheadedness; drop in blood pressure requiring escalation of fluid or pressor treatment; or need for electrical or pharmacologic cardioversion.
The first suspected episode of each of other supraventricular or unknown narrow-complex tachycardia of at least 30 sec duration following randomization was also documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Endpoints</measure>
    <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
    <description>Number of days in the ICU, of telemetry monitoring, and of total hospital stay.
Non-AF arrhythmias of at least 30 sec duration, including non-AF-SVT, ventricular tachycardia (VT), and ventricular flutter (VF), assessed and adjudicated by the Events Committee.
MACE: Combined total mortality, myocardial infarction, and stroke.
Bleeding, assessed by (a) chest tube output in the 24 hour period following surgery and (b) total number of packed red blood cell (RBC) transfusions from enrollment to end of treatment (hospital discharge or post-op day 10).
Significant adverse events: Discontinuation of study treatment, at the discretion of the treating physicians, for suspected significant allergic reaction, severe gastrointestinal intolerance, significant bleeding, or other side effects requiring discontinuation.
Thirty-day mortality assessed
One-year mortality assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1516</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acid capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive Oil capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega -3 fatty acids</intervention_name>
    <description>10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
    <arm_group_label>Omega-3 fatty acid capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olive Oil capsules</description>
    <arm_group_label>Olive Oil capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Scheduled for CS on the following day or later, including coronary artery bypass,
             valve surgery, any other open cardiac surgery (i.e., that includes opening of the
             pericardium), or any combination.

          -  Sinus rhythm on current ECG (sinus bradycardia, sinus tachycardia, and ectopy are
             acceptable).

        Exclusion Criteria:

          -  Regular use (3 or more days/week) of fish oil within the past 4 weeks.

          -  Known allergy or intolerance to fish oil or corn oil.

          -  Currently pregnant.

          -  Unable to provide informed written consent.

          -  Current or planned cardiac transplant or LVAD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Mozaffarian, MD DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Marchioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory of Clinical Epidemiology of Cardiovascular Disease Department of Clinical Pharmacology and Epidemiology Consorzio Mario Negri Sud Via Nazionale 8/A S. Maria Imbaro (Chieti), 66030 ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US, Italy and Argentina</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <results_first_submitted>July 26, 2013</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Dariush Mozaffarian, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1,516 patients scheduled for cardiac surgery (CS) across 28 centers in the US, Italy, and Argentina, enrolled between Aug 2010 and Jun 2012. Inclusion criteria were broad; the main exclusions were regular use of fish oil or absence of sinus rhythm at enrollment. 48% of screened patients and 94% of eligible patients were enrolled.</recruitment_details>
      <pre_assignment_details>Ineligible patients were most often excluded because they were not in sinus rhythm (40.5%), were on fish oil (28.9%), or were unwilling to provide informed consent (23.5%).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olive Oil Capsule</title>
          <description>Placebo : Olive Oil capsules All patients were randomized to receive n-3 Polyunsaturated fatty acids (PUFA) or matched placebo in equal numbers using computer-generated numbers, stratified by medical center.
Treatment: Either oral n-3 PUFA (1 g capsules, each containing ~850 mg of EPA+DHA) or matching placebo (olive oil, 1 g capsules).
Total loading dose = 8 g over 2 to 4 days pre-op, followed by 2 g/d post-op until hospital discharge or until post-op day 10, whichever sooner.</description>
        </group>
        <group group_id="P2">
          <title>Omega-3 Fatty Acid Capsules</title>
          <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="758"/>
                <participants group_id="P2" count="758"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="704"/>
                <participants group_id="P2" count="717"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death/Withdrew/Criteria Violation</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients scheduled for cardiac surgery across 28 centers in the US, Italy, and Argentina, enrolled between Aug 2010 and Jun 2012. Inclusion criteria were broad; the main exclusions were regular use of fish oil or absence of sinus rhythm at enrollment. Forty-eight percent of screened patients and 94% of eligible patients were enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Olive Oil Capsule</title>
          <description>Placebo : Olive Oil capsules</description>
        </group>
        <group group_id="B2">
          <title>Omega-3 Fatty Acid Capsules</title>
          <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="758"/>
            <count group_id="B2" value="758"/>
            <count group_id="B3" value="1516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="12.4"/>
                    <measurement group_id="B2" value="63.8" spread="12.6"/>
                    <measurement group_id="B3" value="63.7" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="551"/>
                    <measurement group_id="B3" value="1094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Any First Post-op Atrial Fibrillation or Flutter (AF)</title>
        <description>Primary: Occurrence of post-CS AF (atrial fibrillation or flutter) of at least 30 seconds duration and confirmed by rhythm strip or 12-lead ECG. This will include definite AF and probable AF (SVT likely to be AF depending on rate and other characteristics).</description>
        <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olive Oil Capsule</title>
            <description>Placebo : Olive Oil capsules</description>
          </group>
          <group group_id="O2">
            <title>Omega-3 Fatty Acid Capsules</title>
            <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Any First Post-op Atrial Fibrillation or Flutter (AF)</title>
          <description>Primary: Occurrence of post-CS AF (atrial fibrillation or flutter) of at least 30 seconds duration and confirmed by rhythm strip or 12-lead ECG. This will include definite AF and probable AF (SVT likely to be AF depending on rate and other characteristics).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-op Af</title>
        <description>Secondary AF endpoints included post-op AF that was sustained (&gt;1 hour), symptomatic, or treated with pharmacological or electrical cardioversion; post-op AF excluding atrial flutter; time to first post-op AF; and the number of post-op AF episodes per patient. OPERA also evaluated the total number of in-hospital days in which any post-op AF, including sustained post-op AF, was present; and the proportion of in-hospital days free of any post-op AF. All potential episodes of post-op AF and other tachyarrhythmias were reviewed and adjudicated by a centralized Events Committee of cardiac electrophysiologists. Additional endpoints included resource utilization, major adverse cardiovascular events (MACE), arterial thromboembolism, and 30-day mortality.</description>
        <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olive Oil Capsule</title>
            <description>Placebo : Olive Oil capsules</description>
          </group>
          <group group_id="O2">
            <title>Omega-3 Fatty Acid Capsules</title>
            <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-op Af</title>
          <description>Secondary AF endpoints included post-op AF that was sustained (&gt;1 hour), symptomatic, or treated with pharmacological or electrical cardioversion; post-op AF excluding atrial flutter; time to first post-op AF; and the number of post-op AF episodes per patient. OPERA also evaluated the total number of in-hospital days in which any post-op AF, including sustained post-op AF, was present; and the proportion of in-hospital days free of any post-op AF. All potential episodes of post-op AF and other tachyarrhythmias were reviewed and adjudicated by a centralized Events Committee of cardiac electrophysiologists. Additional endpoints included resource utilization, major adverse cardiovascular events (MACE), arterial thromboembolism, and 30-day mortality.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sustained, symptomatic, or treated post-op AF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op AF excluding flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Arrhythmias</title>
        <description>The first 3 suspected episodes of atrial fibrillation or flutter of at least 30 sec duration following randomization were documented, including the following information:
Printed or digital rhythm strip and/or 12-lead ECG.
Recording of time of onset and time of cessation.
Additional documentation of temporally associated signs of symptoms, such as new or worsening chest pain, shortness of breath, or lightheadedness; drop in blood pressure requiring escalation of fluid or pressor treatment; or need for electrical or pharmacologic cardioversion.
The first suspected episode of each of other supraventricular or unknown narrow-complex tachycardia of at least 30 sec duration following randomization was also documented.</description>
        <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olive Oil Capsule</title>
            <description>Placebo : Olive Oil capsules</description>
          </group>
          <group group_id="O2">
            <title>Omega-3 Fatty Acid Capsules</title>
            <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Arrhythmias</title>
          <description>The first 3 suspected episodes of atrial fibrillation or flutter of at least 30 sec duration following randomization were documented, including the following information:
Printed or digital rhythm strip and/or 12-lead ECG.
Recording of time of onset and time of cessation.
Additional documentation of temporally associated signs of symptoms, such as new or worsening chest pain, shortness of breath, or lightheadedness; drop in blood pressure requiring escalation of fluid or pressor treatment; or need for electrical or pharmacologic cardioversion.
The first suspected episode of each of other supraventricular or unknown narrow-complex tachycardia of at least 30 sec duration following randomization was also documented.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Other supraventricular tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular tachycardia or fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Endpoints</title>
        <description>Number of days in the ICU, of telemetry monitoring, and of total hospital stay.
Non-AF arrhythmias of at least 30 sec duration, including non-AF-SVT, ventricular tachycardia (VT), and ventricular flutter (VF), assessed and adjudicated by the Events Committee.
MACE: Combined total mortality, myocardial infarction, and stroke.
Bleeding, assessed by (a) chest tube output in the 24 hour period following surgery and (b) total number of packed red blood cell (RBC) transfusions from enrollment to end of treatment (hospital discharge or post-op day 10).
Significant adverse events: Discontinuation of study treatment, at the discretion of the treating physicians, for suspected significant allergic reaction, severe gastrointestinal intolerance, significant bleeding, or other side effects requiring discontinuation.
Thirty-day mortality assessed
One-year mortality assessed</description>
        <time_frame>up to 10 days post-surgery or discharge, whichever sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olive Oil Capsule</title>
            <description>Placebo : Olive Oil capsules</description>
          </group>
          <group group_id="O2">
            <title>Omega-3 Fatty Acid Capsules</title>
            <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Endpoints</title>
          <description>Number of days in the ICU, of telemetry monitoring, and of total hospital stay.
Non-AF arrhythmias of at least 30 sec duration, including non-AF-SVT, ventricular tachycardia (VT), and ventricular flutter (VF), assessed and adjudicated by the Events Committee.
MACE: Combined total mortality, myocardial infarction, and stroke.
Bleeding, assessed by (a) chest tube output in the 24 hour period following surgery and (b) total number of packed red blood cell (RBC) transfusions from enrollment to end of treatment (hospital discharge or post-op day 10).
Significant adverse events: Discontinuation of study treatment, at the discretion of the treating physicians, for suspected significant allergic reaction, severe gastrointestinal intolerance, significant bleeding, or other side effects requiring discontinuation.
Thirty-day mortality assessed
One-year mortality assessed</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE, in-hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total mortality, 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olive Oil Capsule</title>
          <description>Placebo : Olive Oil capsules</description>
        </group>
        <group group_id="E2">
          <title>Omega-3 Fatty Acid Capsules</title>
          <description>Omega -3 fatty acids : 10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="758"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="758"/>
              </event>
              <event>
                <sub_title>Bone marrow or coalgulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="60" subjects_affected="54" subjects_at_risk="758"/>
                <counts group_id="E2" events="50" subjects_affected="44" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal, hepatobiliary, or pancreas</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="758"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="758"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="758"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic or laboratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology or musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="758"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal or genitourinary</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="758"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow or coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="758"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal, hepatobiliary, or pancreas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic or laboratory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology or musculoskeletal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal or genitourinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="758"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Best-practice guidelines for preventing post-op atrial fibrillation were recommended to Centers. The duration prior to surgery may have been too short to be effective; or the dose of n-3 PUFA too low to produce benefit</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Namasha Schelling</name_or_title>
      <organization>Harvard School of Public Health</organization>
      <phone>617-432-1734</phone>
      <email>nschelling@hsph.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

